Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 6/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 6/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 4/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827742 | 0.87 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL827805 | 0.87 | NPC1 (0.40) | KCNQ3KCNQ2TGFBR1GSK3BNPC1 | |
| SCHEMBL827997 | 0.86 | SYK (0.39) | TRPV3TGFBR1GSK3BJAK2 | |
| SCHEMBL827758 | 0.85 | NPC1 (0.39) | TGFBR1GSK3BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL827490 | 0.77 | TGFBR1 (0.34) | TGFBR1GSK3BJAK2 | |
| SCHEMBL3655458 | 0.77 | KDM4E (0.34) | GSK3BAXLNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3032363 | 0.77 | KDM4E (0.34) | GSK3BNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL3032356 | 0.77 | KDM4E (0.34) | GSK3BNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL3657282 | 0.74 | KDM4E (0.36) | GSK3BNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL3657283 | 0.74 | KDM4E (0.36) | GSK3BNPC1RAB9ASMN1; SMN2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010516-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-02 | — | — | EP | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| WO-2007118903-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | KCNQ3 549/4885KCNQ2 656/4885KCNE1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.